Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for XBiotech Inc. (XBIT : NSDQ)
 
 • Company Description   
XBiotech Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing True Human(TM) monoclonal antibodies for treating diseases. XBiotech Inc. is based in AUSTIN, United States.

Number of Employees: 97

 
 • Price / Volume Information   
Yesterday's Closing Price: $5.61 Daily Weekly Monthly
20 Day Moving Average: 139,324 shares
Shares Outstanding: 30.44 (millions)
Market Capitalization: $170.76 (millions)
Beta: 1.42
52 Week High: $18.46
52 Week Low: $5.50
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.08% -19.00%
12 Week -42.76% -37.07%
Year To Date -49.60% -37.21%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
5217 Winnebago Ln
-
AUSTIN,TX 78744
USA
ph: 512-386-2900
fax: 512-386-5505
swhitehurst@xbiotech.com http://www.xbiotech.com
 
 • General Corporate Information   
Officers
John Simard - Chief Executive Officer
Queena Han - Vice President of Finance & Human Resources
W. Thorpe McKenzie - Director
Jan-Paul Waldin - Director
Donald MacAdam - Director

Peer Information
XBiotech Inc. (CORR.)
XBiotech Inc. (RSPI)
XBiotech Inc. (CGXP)
XBiotech Inc. (BGEN)
XBiotech Inc. (GTBP)
XBiotech Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 98400H102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 30.44
Most Recent Split Date: (:1)
Beta: 1.42
Market Capitalization: $170.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.64
Price/Cash Flow: -
Price / Sales: 12.16
EPS Growth
vs. Year Ago Period: -100.00%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -89.69%
vs. Previous Quarter: -88.89%
ROE
03/31/22 - -6.99
12/31/21 - -5.60
09/30/21 - -3.86
ROA
03/31/22 - -6.86
12/31/21 - -5.51
09/30/21 - -3.81
Current Ratio
03/31/22 - 84.05
12/31/21 - 71.49
09/30/21 - 64.81
Quick Ratio
03/31/22 - 84.05
12/31/21 - 71.49
09/30/21 - 64.81
Operating Margin
03/31/22 - -144.13
12/31/21 - -94.67
09/30/21 - -91.99
Net Margin
03/31/22 - -144.13
12/31/21 - -94.67
09/30/21 - -91.99
Pre-Tax Margin
03/31/22 - -205.55
12/31/21 - -138.40
09/30/21 - -143.05
Book Value
03/31/22 - 8.72
12/31/21 - 8.86
09/30/21 - 9.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©